| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 2.601 | 13.525 | 17.896 | 12.278 | 14.862 | 20.392 | 18.057 | 22.156 | 29.162 | 26.712 |
| Total Income - EUR | 2.601 | 13.525 | 17.896 | 12.278 | 14.862 | 20.438 | 18.057 | 22.156 | 29.162 | 26.712 |
| Total Expenses - EUR | 5.685 | 6.133 | 6.384 | 5.504 | 8.589 | 9.341 | 7.436 | 9.291 | 17.845 | 17.204 |
| Gross Profit/Loss - EUR | -3.085 | 7.392 | 11.512 | 6.774 | 6.273 | 11.097 | 10.622 | 12.865 | 11.317 | 9.508 |
| Net Profit/Loss - EUR | -3.163 | 6.986 | 10.975 | 6.406 | 5.828 | 10.674 | 10.284 | 12.334 | 11.069 | 8.827 |
| Employees | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 |
Check the financial reports for the company - Endoclat Med Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 15.315 | 15.159 | 14.903 | 14.629 | 14.346 | 14.074 | 13.762 | 13.805 | 13.763 | 13.686 |
| Current Assets | 1.160 | 2.657 | 12.403 | 17.952 | 23.071 | 4.008 | 10.533 | 2.711 | 6.236 | 13.493 |
| Inventories | 0 | 0 | 0 | 43 | 0 | 662 | 647 | 649 | 647 | 643 |
| Receivables | 1.054 | 2.550 | 3.179 | 1.104 | 1.124 | 2.102 | 1.356 | 1.472 | 1.824 | 7.463 |
| Cash | 105 | 107 | 9.224 | 16.805 | 21.947 | 1.244 | 8.530 | 590 | 3.766 | 5.386 |
| Shareholders Funds | 7.302 | 14.214 | 24.948 | 30.896 | 36.125 | 13.036 | 23.032 | 13.132 | 16.074 | 24.811 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 9.253 | 3.682 | 2.435 | 1.761 | 1.367 | 5.119 | 1.335 | 3.456 | 3.997 | 2.368 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "8622 - 8622" | |||||||||
| CAEN Financial Year |
8621
|
|||||||||
Comments - Endoclat Med Srl